JP2002506527A - マルチプルユニットシステムの用量レベル特性決定方法および工業的プロセス - Google Patents
マルチプルユニットシステムの用量レベル特性決定方法および工業的プロセスInfo
- Publication number
- JP2002506527A JP2002506527A JP50425899A JP50425899A JP2002506527A JP 2002506527 A JP2002506527 A JP 2002506527A JP 50425899 A JP50425899 A JP 50425899A JP 50425899 A JP50425899 A JP 50425899A JP 2002506527 A JP2002506527 A JP 2002506527A
- Authority
- JP
- Japan
- Prior art keywords
- subunits
- individually
- subunit
- multiple unit
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.物理化学的性質、機能性および/または品質のような、個々のサブユニット (12)の複数からなるマルチプルユニットシステムの用量レベル特性の決定のた めの方法であって、それぞれの個々に分析されたサブユニット(12)の正確な特 性を得るためいくつかのサブユニット(12)を個々に分析する工程と、それぞれ の個々に分析されたサブユニット(12)の前記のようにして得られた正確な特性 に基づきマルチプルユニットシステムの用量レベルを決定する工程を特徴とする 、上記方法。 2.マルチプルユニットシステムが錠剤またはカプセルのような医薬マルチプル ユニット用量処方物である請求項1に記載の方法。 3.個々に分析されるサブユニット(12)の数がマルチプルユニットシステムに 含まれるサブユニット(12)の数と、用量レベル特性の決定の統計的正確さに応 じて決定される請求項1記載の方法。 4.個々に分析されるサブユニット(12)の数が本質的にマルチプルユニットシ ステムの完全な用量に含まれるサブユニット(12)の数と等しい請求項3記載の 方法。 5.サブユニット(12)が少なくとも一種の活性薬を含む請求項1〜4のいずれ か一項に記載の方法。 6.サブユニット(12)が保護フィルムを有する請求項1〜5のいずれか一項に 記載の方法。 7.保護フィルムが活性薬の制御された放出を与える請求項5または6に記載の 方法。 8.保護フィルムが腸溶コーティングポリマーである請求項6に記載の方法。 9.いくつかのサブユニット(12)を個々に分析する工程が、サブユニッ ト(12)を並行して個々に分析することにより実施される請求項1〜8のいずれ か一項に記載の方法。 10.サブユニット(12)を個々に分析する工程が、サブユニット(12)の破壊的 テストを実施する工程からなる請求項1〜9のいずれか一項に記載の方法。 11.破壊的テストが溶解テストからなり、それぞれ分析されるサブユニット(1 2)の正確な溶解特性が個々にモニターされ、マルチプルユニットシステムの用 量レベル溶解特性が個々に分析されたサブユニット(12)の得られた溶解特性に 基づき決定される請求項10に記載の方法。 12.溶解テストが吸収分光測定法、発光分光測定法、散乱分光測定法および電気 化学的技術からなる群より選ばれた技術によりモニターされる請求項11に記載の 方法。 13.溶解テストが、UV−VIS、IR、またはNIR分光測定法のような吸収 分光測定法によりモニターされる請求項12に記載の方法。 14.溶解テストが、複数のウェル(16)を有するマイクロプレート(14)を有す るマイクロプレート型分光光度計を使用し、かつ個々に分析されるそれぞれのサ ブユニット(12)がウェル(16)のそれぞれ一つに配置される請求項11〜13の いずれか一項に記載の方法。 15.マイクロプレート(14)が分析の際にサブユニット(12)からの干渉を避け るために傾いている請求項14に記載の方法。 16.サブユニット(12)からの干渉を避けるために、それぞれのウェル(16)に 存在するサブユニット(12)が分光光度計からの光学路と干渉しないようにマイ クロプレート(14)が分析の際に揺らされる請求項14または15に記載の方法。 17.サブユニット(12)からの干渉を避けるために、それぞれのウェルの 内容が攪拌される請求項14〜16のいずれか一項に記載の方法。 18.攪拌がそれぞれのウェル内のガラスビーズによる請求項17に記載の方法。 19.サブユニット(12)を個々に分析する工程が、それぞれ分析されるサブユニ ット(12)の非破壊的テストを実施する工程からなる請求項1〜9のいずれか一 項に記載の方法。 20.製造されたマルチプルユニットシステム処方物のあらかじめ決められた用量 レベル特性を得るために、それぞれ個々に分析されたサブユニット(12)につい て得られた正確な特性がフィードバックデータとしてプロセスで使用される請求 項1〜19のいずれか一項に記載の方法を含むマルチプルユニットシステム処方物 の製造の工業的プロセス。 21.マルチプルユニットシステム処方製品をデザインするためのプロセスにおい て使用する請求項1〜19のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9702338A SE9702338D0 (sv) | 1997-06-18 | 1997-06-18 | An analytical method and industrial process including the same |
SE9702338-6 | 1997-06-18 | ||
PCT/SE1998/001094 WO1998058254A1 (en) | 1997-06-18 | 1998-06-08 | A method and an industrial process for determining dose-level characteristics of a multiple unit system |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002506527A true JP2002506527A (ja) | 2002-02-26 |
JP2002506527A5 JP2002506527A5 (ja) | 2005-12-22 |
Family
ID=20407428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50425899A Ceased JP2002506527A (ja) | 1997-06-18 | 1998-06-08 | マルチプルユニットシステムの用量レベル特性決定方法および工業的プロセス |
Country Status (11)
Country | Link |
---|---|
US (1) | US6162465A (ja) |
EP (1) | EP0988542B1 (ja) |
JP (1) | JP2002506527A (ja) |
KR (1) | KR20010013910A (ja) |
CN (1) | CN1153965C (ja) |
AT (1) | ATE356993T1 (ja) |
AU (1) | AU722369B2 (ja) |
CA (1) | CA2293586A1 (ja) |
DE (1) | DE69837330D1 (ja) |
SE (1) | SE9702338D0 (ja) |
WO (1) | WO1998058254A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014522991A (ja) * | 2011-08-08 | 2014-09-08 | アプタリス ファーマ リミテッド | 消化酵素を含む組成物の溶出試験の方法 |
US9884025B2 (en) | 2000-11-15 | 2018-02-06 | Aptalis Pharma S.R.L. | Microspheres of pancreatic enzymes with high stability and production method thereof |
US10087493B2 (en) | 2008-03-07 | 2018-10-02 | Aptalis Pharma Canada Ulc | Method for detecting infectious parvovirus in pharmaceutical preparations |
US10184121B2 (en) | 2013-06-28 | 2019-01-22 | Allergan Pharmaceuticals International Limited | Methods for removing viral contaminants from pancreatic extracts |
US10206882B2 (en) | 2007-02-20 | 2019-02-19 | Allergan Pharmaceuticals International Limited | Stable digestive enzyme compositions |
US10993996B2 (en) | 2013-08-09 | 2021-05-04 | Allergan Pharmaceuticals International Limited | Digestive enzyme composition suitable for enteral administration |
US11364205B2 (en) | 2010-10-01 | 2022-06-21 | Societe Des Produits Nestle S.A. | Stable low digestive enzyme content formulation |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9802537D0 (sv) * | 1998-07-13 | 1998-07-13 | Astra Ab | Method for controlling a coating process |
US6764651B2 (en) * | 2001-11-07 | 2004-07-20 | Varian, Inc. | Fiber-optic dissolution systems, devices, and methods |
US6773282B2 (en) * | 2002-11-26 | 2004-08-10 | Verizon Services Corp. | Modular telephone jack for multi-occupant dwelling |
US20050171436A1 (en) * | 2004-01-09 | 2005-08-04 | Clarke Richard H. | Raman spectroscopy for monitoring drug-eluting medical devices |
FI20050385A0 (fi) * | 2005-04-14 | 2005-04-14 | Jukka Rantanen | Menetelmä ja laitteisto kiinteän aineen liuottamiseksi nesteeseen |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5733353A (en) * | 1980-08-06 | 1982-02-23 | Furonto Sangyo Kk | Tester for physical properties of solid agent |
US4994260A (en) * | 1982-05-28 | 1991-02-19 | Astra Lakemedel Aktiebolag | Pharmaceutical mixture |
US4772475A (en) * | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
SE450087B (sv) * | 1985-10-11 | 1987-06-09 | Haessle Ab | Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial |
SE455836B (sv) * | 1985-10-11 | 1988-08-15 | Haessle Ab | Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning |
SE8605515D0 (sv) * | 1986-12-22 | 1986-12-22 | Astra Laekemedel Ab | A liquid dosage form for oral administration of a pharmaceutically active substance |
US5688519A (en) * | 1987-04-06 | 1997-11-18 | Leonard; Robert J. | Flash-flow fused medicinal implants |
DE4101677A1 (de) * | 1991-01-22 | 1992-07-23 | Repenning Heimke | Verfahren zur bestimmung der wirksamkeit von arzneimitteln in abhaengigkeit der zur herstellung und stabiliaet dienenden hilfstoffe |
-
1997
- 1997-06-18 SE SE9702338A patent/SE9702338D0/xx unknown
-
1998
- 1998-06-08 DE DE69837330T patent/DE69837330D1/de not_active Expired - Lifetime
- 1998-06-08 KR KR1019997011932A patent/KR20010013910A/ko not_active Application Discontinuation
- 1998-06-08 AU AU77946/98A patent/AU722369B2/en not_active Ceased
- 1998-06-08 JP JP50425899A patent/JP2002506527A/ja not_active Ceased
- 1998-06-08 AT AT98926018T patent/ATE356993T1/de not_active IP Right Cessation
- 1998-06-08 CN CNB988062151A patent/CN1153965C/zh not_active Expired - Fee Related
- 1998-06-08 WO PCT/SE1998/001094 patent/WO1998058254A1/en active IP Right Grant
- 1998-06-08 EP EP98926018A patent/EP0988542B1/en not_active Expired - Lifetime
- 1998-06-08 US US09/101,114 patent/US6162465A/en not_active Expired - Fee Related
- 1998-06-08 CA CA002293586A patent/CA2293586A1/en not_active Abandoned
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9884025B2 (en) | 2000-11-15 | 2018-02-06 | Aptalis Pharma S.R.L. | Microspheres of pancreatic enzymes with high stability and production method thereof |
US10206882B2 (en) | 2007-02-20 | 2019-02-19 | Allergan Pharmaceuticals International Limited | Stable digestive enzyme compositions |
US10087493B2 (en) | 2008-03-07 | 2018-10-02 | Aptalis Pharma Canada Ulc | Method for detecting infectious parvovirus in pharmaceutical preparations |
US11364205B2 (en) | 2010-10-01 | 2022-06-21 | Societe Des Produits Nestle S.A. | Stable low digestive enzyme content formulation |
JP2014522991A (ja) * | 2011-08-08 | 2014-09-08 | アプタリス ファーマ リミテッド | 消化酵素を含む組成物の溶出試験の方法 |
US9976171B2 (en) | 2011-08-08 | 2018-05-22 | Allergan Pharmaceuticals International Limited | Method for dissolution testing of solid compositions containing digestive enzymes |
US10184121B2 (en) | 2013-06-28 | 2019-01-22 | Allergan Pharmaceuticals International Limited | Methods for removing viral contaminants from pancreatic extracts |
US10993996B2 (en) | 2013-08-09 | 2021-05-04 | Allergan Pharmaceuticals International Limited | Digestive enzyme composition suitable for enteral administration |
Also Published As
Publication number | Publication date |
---|---|
KR20010013910A (ko) | 2001-02-26 |
AU722369B2 (en) | 2000-08-03 |
CN1153965C (zh) | 2004-06-16 |
CA2293586A1 (en) | 1998-12-23 |
EP0988542B1 (en) | 2007-03-14 |
SE9702338D0 (sv) | 1997-06-18 |
ATE356993T1 (de) | 2007-04-15 |
US6162465A (en) | 2000-12-19 |
DE69837330D1 (de) | 2007-04-26 |
WO1998058254A1 (en) | 1998-12-23 |
CN1260878A (zh) | 2000-07-19 |
AU7794698A (en) | 1999-01-04 |
EP0988542A1 (en) | 2000-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Blanco et al. | Monitoring powder blending in pharmaceutical processes by use of near infrared spectroscopy | |
Kirsch et al. | Near-infrared spectroscopic monitoring of the film coating process | |
Otsuka | Comparative particle size determination of phenacetin bulk powder by using Kubelka–Munk theory and principal component regression analysis based on near-infrared spectroscopy | |
JP2002506527A (ja) | マルチプルユニットシステムの用量レベル特性決定方法および工業的プロセス | |
Locatelli et al. | Recent application of analytical methods to phase I and phase II drugs development: A review | |
Li et al. | Measurement of drug agglomerates in powder blending simulation samples by near infrared chemical imaging | |
CN106841100A (zh) | 一种基于近红外光谱技术的小规格口服固体制剂中活性药物成分快速测定方法 | |
Rezk et al. | Quantification of amlodipine and atorvastatin in human plasma by UPLC–MS/MS method and its application to a bioequivalence study | |
Kirchmeyer et al. | Influence of excipients on solvent-mediated hydrate formation of piroxicam studied by dynamic imaging and fractal analysis | |
Jede et al. | In-line derivative spectroscopy as a promising application to a small-scale in vitro transfer model in biorelevant supersaturation and precipitation testing | |
Silva et al. | Monitoring microsphere coating processes using PAT tools in a bench scale fluid bed | |
Farid et al. | A new HPLC methodology for the analysis of metronidazole and dexibuprofen: Application to pharmacokinetic study and comparative greenness assessment | |
Hasan et al. | A key approach on dissolution of pharmaceutical dosage forms | |
Sun et al. | Qualitative and quantitative assessment of the HPLC fingerprints of Ginkgo biloba extract by the involution similarity method | |
Chaudhari et al. | A brief review on determination of acenocoumarol in biological and pharmaceutical specimens: analytical methodologies | |
Domike et al. | Light induced fluorescence for predicting API content in tablets: Sampling and error | |
Abd Allah et al. | Fully validated UPLC–MS/MS method for quantifying Favipiravir in human plasma boosted lean six sigma: an application for a bioequivalence study | |
El-Shorbagy et al. | Innovative derivative/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage units | |
Andrade et al. | Comparison of multivariate calibration methods to determine simultaneously mebendazole–cambendazole and mebendazole–thiabendazole in pharmaceutical preparations by UV–visible spectrophotometry | |
Layloff | Scientific Fingerprinting: A Pharmaceutical Regulatory Tool. | |
Anwer et al. | Design and strategy for spectrofluorimetric determination of tranexamic acid in its authentic form and pharmaceutical preparations: application to spiked human plasma | |
Mekasha | Pharmaceutical solid oral dosage form analysis: Literature review | |
Aymen et al. | Raman spectroscopy for the quantitative analysis of Lornoxicam in solid dosage forms | |
Siew | Understanding Dissolution Testing | |
Brashear et al. | Diffuse reflectance near‐infrared spectroscopy as a nondestructive analytical technique for polymer implants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050608 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050608 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050608 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080513 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20081007 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081202 |